List of Excipients in Branded Drug OXCARBAZEPINE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	OXCARBAZEPINE	oxcarbazepine	0781-6270	ALCOHOL
Sandoz Inc	OXCARBAZEPINE	oxcarbazepine	0781-6270	ASCORBIC ACID
Sandoz Inc	OXCARBAZEPINE	oxcarbazepine	0781-6270	CELLULOSE, MICROCRYSTALLINE

Generic Drugs Containing OXCARBAZEPINE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	oxcarbazepine	0054-0199	ASCORBIC ACID
Hikma Pharmaceuticals USA Inc	oxcarbazepine	0054-0199	CARBOXYMETHYLCELLULOSE SODIUM
Hikma Pharmaceuticals USA Inc	oxcarbazepine	0054-0199	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in OXCARBAZEPINE?

# Of NDCs	Excipient
26	ALUMINUM OXIDE
18	ASCORBIC ACID
1	CARBOXYMETHYLCELLULOSE

Oxcarbazepine Excipient Strategy and Commercial Opportunities

Last updated: November 8, 2026

Oxcarbazepine is a mature small-molecule antiepileptic with low formulation risk for immediate-release tablets and higher commercial value in extended-release, liquid, pediatric, and patient-friendly dosage forms. The core opportunity is no longer basic molecule commercialization. It is differentiated delivery that improves dosing convenience, swallowing, adherence, or exposure control while avoiding new safety liabilities.

The immediate-release market is generic and price competitive. Oxtellar XR, the extended-release product marketed by Supernus Pharmaceuticals, remains the principal branded formulation opportunity. Oxcarbazepine is not a biologic, so biosimilar competition is irrelevant. Competitive threats come from ANDA products, 505(b)(2) formulations, private-label generics, and reformulations with improved administration characteristics.

What is the FDA status of oxcarbazepine products?

Oxcarbazepine is FDA-approved for partial seizures and is marketed in immediate-release tablets, oral suspension, and extended-release tablets.

Product	Active ingredient	Dosage form	Sponsor or historical sponsor	FDA pathway	Commercial position
Trileptal	Oxcarbazepine	Immediate-release tablets	Novartis	NDA	Reference product; generic market
Trileptal	Oxcarbazepine	Oral suspension	Novartis	NDA	Pediatric and swallowing-related use
Oxtellar XR	Oxcarbazepine	Extended-release tablets	Supernus Pharmaceuticals	505(b)(2) NDA	Branded differentiated product
Generic oxcarbazepine	Oxcarbazepine	Immediate-release tablets	Multiple ANDA sponsors	505(j)	Mature, price-driven market

Trileptal was initially approved in the United States in 2000. Oxtellar XR received FDA approval in 2013 for once-daily treatment of partial seizures in adults and children aged six years and older, subject to the product labeling and dosing requirements.[1][2]

Oxcarbazepine is converted rapidly to 10-monohydroxy derivative, or MHD, which provides most of the pharmacological activity. Formulation development must therefore control oxcarbazepine dissolution and the resulting MHD exposure rather than rely only on conventional in vitro release data.[1]

What excipient properties matter most for oxcarbazepine?

Oxcarbazepine has limited aqueous solubility, making wetting, particle size, solid-state control, and dissolution the main formulation variables. The commercial formulation challenge is not extreme insolubility, but achieving reproducible absorption across dose strengths and dosage forms.

Key excipient functions include:

Formulation need	Relevant excipient classes	Main development objective
Improve wetting and dissolution	Surfactants, wetting agents, hydrophilic polymers	Reduce dissolution variability
Improve powder flow	Colloidal silicon dioxide, silica-based glidants	Support robust tableting
Increase compactibility	Microcrystalline cellulose, lactose, dibasic calcium phosphate	Achieve tablet hardness without excessive disintegration time
Control release	Hypromellose, ethylcellulose, methacrylate polymers	Produce once-daily exposure
Maintain suspension	Xanthan gum, cellulose derivatives, carbomers	Prevent settling and dose nonuniformity
Improve taste	Sweeteners, flavors, ion-exchange resins, polymer coatings	Increase pediatric acceptability
Protect product quality	Antioxidants, preservatives, moisture barriers	Control degradation and microbial growth

The active pharmaceutical ingredient should be evaluated for particle-size distribution, polymorphic form, crystallinity, bulk density, and moisture sensitivity. These attributes affect blend uniformity, tablet compression, dissolution, and suspension sedimentation.

Which excipients are used in immediate-release oxcarbazepine tablets?

Immediate-release tablets generally use conventional fillers, binders, disintegrants, glidants, and lubricants. Trileptal tablet labeling identifies excipients including microcrystalline cellulose, crospovidone, hypromellose, povidone, colloidal silicon dioxide, magnesium stearate, talc, and titanium dioxide, with colorants varying by strength.[3]

Recommended immediate-release architecture

A practical generic formulation can use:

• Microcrystalline cellulose as the principal filler and compression aid.
• Lactose or another soluble filler where additional dissolution support is needed.
• Crospovidone or croscarmellose sodium for rapid tablet breakup.
• Povidone or copovidone as a binder if wet granulation is required.
• Colloidal silicon dioxide for flow improvement.
• Magnesium stearate at controlled concentration and mixing time.

The main technical risk is over-lubrication. Excess magnesium stearate can reduce tablet wettability and slow oxcarbazepine dissolution. Formulators should establish a dissolution method that can detect changes in lubricant concentration, granulation endpoint, compression force, and API particle size.

Direct compression is commercially attractive because it reduces manufacturing steps. Wet granulation may be preferable where oxcarbazepine has poor flow, low bulk density, or segregation risk across dose strengths. Roller compaction is another option for a moisture-sensitive process, but it can create dense granules that slow dissolution.

For generic substitution, the formulation should target rapid and consistent release across all strengths. The product should avoid excipient changes that create food effects, altered gastric transit, or delayed conversion to MHD.

What formulation strategy is best for oxcarbazepine oral suspension?

The oral suspension is the strongest conventional opportunity for pediatric and dysphagia-focused differentiation. Trileptal oral suspension contains suspending and wetting components, sweeteners, flavors, and preservatives intended to maintain dose uniformity and acceptability.[4]

A commercial suspension should address five performance requirements:

1. Uniform concentration after storage and shaking.
2. Rapid redispersion after settling.
3. Accurate dosing with an oral syringe.
4. Acceptable taste after repeated administration.
5. Chemical and microbiological stability over the labeled shelf life.

Suspension excipient strategy

A cellulose-based or xanthan-gum suspending system can provide a useful balance between viscosity and pourability. Excessive viscosity increases dosing errors and makes withdrawal through an oral syringe difficult. The formulation should be tested at refrigerated, room-temperature, and accelerated conditions because viscosity and sedimentation can change with temperature.

Potential approaches include:

• Xanthan gum or hydroxyethylcellulose for suspension stability.
• Polysorbate or another wetting agent to disperse hydrophobic API particles.
• Glycerin, sorbitol, or other polyols to improve mouthfeel and reduce sediment packing.
• Sodium saccharin, sucralose, or equivalent sweeteners for taste correction.
• Fruit flavor systems that mask the bitter or medicinal profile.
• Preservatives selected for compatibility with pH, packaging, and microbial challenge performance.

A preservative-free suspension could create a differentiated product for selected markets, but it would require a validated multidose packaging and microbiological-control strategy. Unit-dose sachets or ready-to-use cups could reduce preservative requirements but would increase packaging and manufacturing costs.

A high-value pediatric product would combine a low-volume concentration, an oral syringe, clear dose markings, and a robust taste-masking system. The formulation should not rely on flavor alone if oxcarbazepine particles remain in the oral cavity.

What excipients protect the Oxtellar XR extended-release opportunity?

Oxtellar XR is the principal branded extended-release formulation opportunity. Its commercial value derives from once-daily dosing and controlled oxcarbazepine release rather than from the underlying molecule.[2]

Extended-release oxcarbazepine generally requires a matrix or multiparticulate system that controls water penetration, polymer hydration, drug diffusion, and matrix erosion. Hypromellose is a common starting point for hydrophilic matrix development. Polymer grade, viscosity, particle size, and concentration have a direct effect on release.

Extended-release formulation options

Hydrophilic matrix tablet

A hydrophilic matrix can use hypromellose with fillers, binders, glidants, and lubricants. Advantages include low manufacturing complexity and scalable tablet production. Risks include dose dumping, sensitivity to tablet geometry, and release changes caused by food, alcohol, or gastrointestinal transit.

Hydrophobic matrix tablet

Ethylcellulose or lipid-based materials can reduce water penetration and produce slower release. These systems may improve robustness but can complicate dissolution development and create greater sensitivity to manufacturing variables.

Multiparticulate capsules

Pelletized or granulated oxcarbazepine coated with functional polymers can provide more consistent gastrointestinal distribution than a single matrix tablet. The tradeoffs are higher manufacturing cost, coating-process complexity, and potential intellectual-property exposure around coating structure and release profile.

Osmotic or membrane-controlled system

An osmotic system could support a differentiated 505(b)(2) product, but the development burden is materially higher. Manufacturing, scale-up, in vitro-in vivo correlation, and device-like performance requirements would reduce the attractiveness relative to a conventional matrix tablet.

Critical extended-release tests

A commercially credible XR program should include:

• Dissolution across multiple pH conditions.
• Fed and fasted pharmacokinetic comparison.
• Alcohol dose-dumping studies.
• Robustness to tablet hardness and coating variation.
• Evaluation across strengths and dose proportionality.
• Assessment of conversion to MHD.
• Stability under high humidity and temperature.
• In vitro release comparison against the reference product where applicable.

A generic XR product needs pharmaceutical equivalence and bioequivalence under the applicable FDA product-specific guidance. A materially different release mechanism may require a 505(b)(2) application rather than an ANDA.

What patent protection covers oxcarbazepine formulations?

The original oxcarbazepine compound and immediate-release product patents are no longer the central barrier to entry in the United States. Protection has shifted toward formulation, release profile, dosing regimen, manufacturing process, and specific product configurations.

Patent category	Relevance to oxcarbazepine	Entry impact
Compound patent	Historical protection for oxcarbazepine	Expired or commercially exhausted in major markets
Immediate-release composition	Historical Trileptal protection	Low barrier for current generic entrants
Extended-release composition	Oxtellar XR-related protection	Primary branded product risk
Method-of-use claims	Partial seizures, dosing schedules, patient populations	May support litigation or labeling restrictions
Manufacturing claims	Granulation, coating, particle size, or release control	Can raise development and freedom-to-operate costs
Suspension claims	Concentration, stabilizer system, taste masking, packaging	Moderate differentiation potential

The FDA Orange Book should be used to confirm the current listed patents, pediatric exclusivity, and patent certifications for Oxtellar XR and other listed products.[5] Patent term depends on the earliest effective nonprovisional filing date, patent-term adjustment, patent-term extension, terminal disclaimers, and any applicable regulatory exclusivity.

How do Paragraph IV challenges affect oxcarbazepine?

For immediate-release oxcarbazepine tablets, Paragraph IV risk is limited because the market is mature and multiple generic products already exist. For Oxtellar XR, a Paragraph IV filing can challenge formulation or method-of-use patents and may trigger Hatch-Waxman litigation and a statutory 30-month stay if the required conditions are met.

The commercial consequences depend on:

• The number of patents listed in the Orange Book.
• Whether the ANDA applicant certifies Paragraph III, Paragraph IV, or a section viii statement.
• Whether the brand holder files an infringement action within the statutory period.
• Whether the challenged claims cover the proposed product or only a narrow formulation.
• Whether a settlement permits a licensed or authorized-generic launch.

A generic applicant may also design around formulation claims by changing matrix polymer levels, coating structure, tablet geometry, or release mechanism. That strategy can reduce patent exposure but may increase bioequivalence risk.

What generic launch scenarios exist for oxcarbazepine?

Immediate-release tablets

This is the lowest-risk and most competitive segment. Generic manufacturers can compete on manufacturing cost, supply reliability, wholesaler access, and strength availability. Margin pressure is likely to remain high.

Oral suspension

The suspension market offers more room for differentiation because taste, settling, dosing devices, and packaging affect physician and caregiver preference. Manufacturing complexity is higher than for tablets, which can reduce the number of reliable competitors.

Extended-release tablets

XR entry has the highest regulatory and patent complexity. A successful entrant must demonstrate bioequivalence while avoiding formulation claims and preserving a commercially acceptable release profile. The market can support better pricing than immediate-release tablets if the branded product retains prescriber preference.

New patient-friendly dosage forms

ODTs, chewable tablets, mini-tablets, sprinkle products, and unit-dose liquids could address adherence and swallowing problems. These products may require a 505(b)(2) pathway if they materially change administration or pharmacokinetics.

What are the strongest commercial opportunities for oxcarbazepine excipients?

The most defensible opportunities are linked to patient use rather than simple excipient substitution.

Opportunity	Commercial rationale	Development complexity
Taste-masked pediatric suspension	Improves administration and caregiver acceptance	Moderate
Low-volume concentrated suspension	Reduces administration burden	Moderate
Once-daily extended-release generic	Competes with Oxtellar XR	High
Sprinkle or mini-tablet product	Addresses swallowing limitations	High
Chewable or orally disintegrating tablet	Expands use in children and dysphagia patients	Moderate to high
Amorphous dispersion	May improve dissolution and reduce variability	High
Nanocrystal or nanosuspension	Potentially improves dissolution	High
Unit-dose liquid packaging	Improves portability and dosing control	Moderate
Excipient platform licensing	Enables differentiated formulation across markets	Moderate

The best near-term opportunity is a stable, palatable oral suspension with accurate dosing and strong packaging. The highest-value opportunity is a once-daily or patient-friendly dosage form with defensible formulation claims. A conventional tablet with a different filler is unlikely to create durable commercial differentiation.

How strong is the oxcarbazepine patent estate?

The estate is asymmetric. Immediate-release oxcarbazepine has limited practical patent protection because the product and generic markets are mature. Extended-release products retain greater value because release technology, dosing regimen, and formulation claims can support exclusivity and litigation.

Patent strength is highest where claims cover:

• A specific release profile tied to pharmacokinetic performance.
• A defined polymer matrix and drug-to-polymer ratio.
• A narrow but commercially necessary tablet architecture.
• A clinically meaningful once-daily dosing regimen.
• A formulation that cannot be easily designed around without losing bioequivalence.

Patent strength is weaker where claims cover broad excipient combinations that can be replaced without changing clinical performance. Process claims also have limited value if competitors can manufacture an equivalent product through a different process.

What FDA and regulatory barriers apply to new oxcarbazepine products?

A conventional immediate-release generic generally follows the ANDA pathway. A new dosage form, new release mechanism, or clinically differentiated product may require a 505(b)(2) NDA.

Key regulatory risks include:

• Failure to demonstrate bioequivalence because of altered dissolution.
• Food-related pharmacokinetic changes.
• Inadequate control of MHD exposure.
• Dose nonuniformity in suspensions.
• Microbial contamination or preservative failure.
• Taste-masking excipients that affect absorption.
• Alcohol-related dose dumping in extended-release products.
• Excipient safety issues in pediatric populations.
• Inadequate device compatibility with oral syringes or unit-dose packaging.

Because oxcarbazepine is a small molecule, biosimilar regulation does not apply. Competitive products are regulated as generics, reformulations, or new drug applications depending on their formulation and clinical claims.

How does oxcarbazepine compare with competing antiepileptic products?

Oxcarbazepine competes with carbamazepine, lamotrigine, levetiracetam, lacosamide, and other antiseizure medicines. Excipient strategy differs by product segment.

Product	Main formulation opportunity	Generic pressure	Differentiation potential
Oxcarbazepine IR	Tablets and suspension	High	Low to moderate
Oxcarbazepine XR	Once-daily controlled release	Moderate	High
Carbamazepine	Extended release, chewables, suspension	High	Moderate
Lamotrigine	ODT, chewable, dispersible forms	High	Moderate
Levetiracetam	Oral solution, XR, injection	High	Moderate
Lacosamide	Tablets, solution, injection	Moderate	Moderate to high

Oxcarbazepine’s main formulation advantage is the ability to combine a well-established oral product with extended-release delivery. Its main disadvantage is the competitive maturity of the immediate-release market and the need to manage conversion to MHD.

Key Takeaways

• Immediate-release oxcarbazepine is a mature generic market with limited formulation-based pricing power.
• Oral suspension is the most practical near-term opportunity for excipient-led differentiation.
• Taste masking, redispersion, dose accuracy, and oral-syringe compatibility are central to pediatric commercial value.
• Extended-release oxcarbazepine has the strongest patent and margin potential but also the highest bioequivalence and litigation risk.
• Hypromellose-based matrix systems are a logical starting point for XR development, subject to dose-dumping and food-effect testing.
• Biosimilar risk does not apply because oxcarbazepine is a small molecule.
• New ODT, chewable, mini-tablet, sprinkle, and unit-dose products could support 505(b)(2) strategies.
• The current commercial value lies in delivery technology, adherence, and patient usability rather than in the active ingredient itself.

FAQs

Is oxcarbazepine suitable for an amorphous solid dispersion?

It may be suitable where dissolution or exposure variability limits performance, but the approach requires solid-state stability, moisture, recrystallization, and scale-up studies. A conventional matrix or suspension may offer a lower-cost development path.

Which excipient is most important for oxcarbazepine extended release?

The release-controlling polymer is usually the most important excipient class. Hypromellose grade, viscosity, concentration, and distribution within the tablet can materially change dissolution and pharmacokinetics.

Can oxcarbazepine be developed as an orally disintegrating tablet?

Yes, but the product must address dose size, taste, tablet friability, disintegration, and dissolution. A high drug load can make ODT development more difficult than conventional immediate-release tablets.

Does oxcarbazepine require a preservative in an oral suspension?

A multidose aqueous suspension generally requires either a validated preservative system or an alternative microbiological-control strategy. Unit-dose packaging can reduce preservative dependence but increases packaging and supply-chain costs.

What is the most attractive licensing opportunity for oxcarbazepine?

A differentiated extended-release or pediatric liquid platform has greater licensing value than a conventional immediate-release tablet. The strongest assets combine demonstrated pharmacokinetics, scalable manufacturing, and formulation claims that are difficult to design around.

References

1. U.S. Food and Drug Administration. (2023). Trileptal (oxcarbazepine) prescribing information.
2. U.S. Food and Drug Administration. (2023). Oxtellar XR (oxcarbazepine extended-release) prescribing information.
3. Novartis Pharmaceuticals Corporation. (n.d.). Trileptal tablets: Inactive ingredients and product information.
4. Novartis Pharmaceuticals Corporation. (n.d.). Trileptal oral suspension: Inactive ingredients and product information.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.